STOCKHOLM, Feb. 19, 2020 /PRNewswire/ --
Important events in 2019
KL1333
- NeuroVive enrolls first subject in its European KL1333 phase
Ia/b clinical
study
- NeuroVive initiates second part of its ongoing KL1333 Phase
Ia/b clinical
study
- NeuroVive completes recruitment of healthy volunteers in the
second part of its ongoing KL1333 clinical Phase Ia/b study
NV354
- NeuroVive initiates NV354 preclinical safety studies and scales
up compound production
NeuroSTAT
- NeuroVive's IND for clinical development of NeuroSTAT approved
by
FDA
- NeuroSTAT receives Fast Track designation from the US Food and
Drug Administration
Financials
- NeuroVive is supplied with approximately MSEK 99.0 in share
issue
proceeds
- NeuroVive receives SEK 28.2
Million in a directed new share issue
Strategy and
communications
- NeuroVive updates its strategy and sharpens its focus on
primary mitochondrial
diseases
- NeuroVive hosts the company's first Capital Markets
Day
- NeuroVive hosts the Mitochondria Day for the second time
Other
- NeuroVive announces settlement in dispute with CicloMulsion
AG
Important events after the reporting
period
- NeuroVive proposes a rights issue of approximately MSEK 74
before issue costs. The rights issue is guaranteed to
90%.
Financial information fourth quarter (Oct-Dec
2019)*
- Net revenues: KSEK 49
(5)
- Other operating income: KSEK 1,000
(1,009)
- Loss before tax: KSEK 27,112
(19,978)
- Loss per share: SEK -0.15
(-0.25)
- Diluted loss per share: SEK -0.15
(-0.25)
Financial information full year 2019 (Jan-Dec
2019)*
- Net revenues: KSEK 34
(5)
- Other operating income: KSEK 3,500
(2,461)
- Loss before tax: KSEK 77,000
(73,494)
- Loss per share: SEK 0.45
(0.94)
- Diluted loss per share: SEK 0.45
(0.94)
* APM Alternative perfomance measures, see definition on page 17
in the Report.
The complete Year End report is available for download below and
through NeuroVive's web site www.neurovive.com.
The information was submitted for publication, through the
agency of the contact person set out below at 08:40 a.m. CET on 19
February 2020.
For more information please contact:
Erik Kinnman, CEO
+46 (0)46-275-62-20
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund,
Sweden
Tel: +46 (0)46-275-62-20 (switchboard)
info@neurovive.com , www.neurovive.com
For news subscription, please
visit http://www.neurovive.com/press-releases/subscription-page/
About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine,
with one project in clinical phase I (KL1333) for chronic treatment
of primary mitochondrial diseases and one project, in preparation
for clinical trials (NV354), for treatment of primary mitochondrial
diseases with Complex I deficiency. NeuroSTAT for traumatic brain
injury (TBI) is ready to enter a clinical phase II efficacy study.
The R&D portfolio also consists of early projects for primary
mitochondrial disease, and NASH. NeuroVive's ambition is to take
drugs for primary mitochondrial diseases through clinical
development and all the way to market, with or without partners.
For the TBI and NASH projects the goal is to enter strategic
partnerships. A subset of compounds under NeuroVive's NVP015
program has been licenced to Fortify Therapeutics, a BridgeBio
company, for local treatment development of Leber's Hereditary
Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is
also traded on the OTC Market's Pink Open market in the US (OTC:
NEVPF).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-year-end-report-january---december-2019,c3038975
The following files are available for download:
|
https://mb.cision.com/Main/6574/3038975/1196579.pdf
|
NeuroVive
Pharmaceutical AB Year End Report January - December
2019
|